Levite M, Reisner Y
Department of Membrane Research and Biophysics, Weizmann Institute of Science, Rehovot, Israel.
Transplantation. 1993 Mar;55(3):633-8. doi: 10.1097/00007890-199303000-00031.
Fully allogeneic C57BL/6-->BALB/c chimeras were grafted at different intervals after bone marrow transplantation with C3H/HeJ skin grafts. We found that the donor-type and host-type skin grafts were always permanently accepted by the allogeneic chimeras, whereas the acceptance or rejection of third-party grafts was dependent on the timing of skin grafting: if grafted later then 3.5 weeks after BMT, they were rejected; if grafted earlier they were accepted for prolonged periods (over 100 days). We further show that 77% of the C57BL/6-->BALB/c chimeras that had been grafted with C3H/HeJ skin within the first 2 weeks post-BMT were still holding the graft 15 weeks after transplantation, as opposed to 11% of the chimeras that had been grafted 8.5 weeks post-BMT. Syngeneic BALB/c-->BALB/c chimeras, in contrast to allogeneic chimeras, promptly rejected the third-party skin grafts even when these grafts were placed within the first 3 weeks after BMT. Thymocytes and splenocytes from allogeneic chimeras that accepted the third-party skin grafts were able to mount relatively strong mixed lymphocytes reactions against the third-party antigens. Grafting of secondary skin grafts from the third-party donor on chimeras that had already accepted such skin grafts led to a prompt rejection of both third-party grafts but not of donor-type skin grafts, suggesting that the immune capacity to reject third-party skin grafts has already been attained in such chimeras. It is therefore suggested that the prolonged tolerance to third-party skin grafts may be associated with the origin of the bone marrow--derived cells in the skin graft.
将完全异基因的C57BL/6→BALB/c嵌合体在骨髓移植后的不同时间间隔用C3H/HeJ皮肤移植物进行移植。我们发现，供体型和宿主型皮肤移植物总是能被异基因嵌合体永久接受，而第三方移植物的接受或排斥取决于皮肤移植的时间：如果在骨髓移植后3.5周后移植，它们会被排斥；如果更早移植，则会被长期接受（超过100天）。我们进一步表明，在骨髓移植后前2周内用C3H/HeJ皮肤移植的C57BL/6→BALB/c嵌合体中，77%在移植后15周仍保留移植物，而在骨髓移植后8.5周移植的嵌合体中这一比例为11%。与异基因嵌合体相反，同基因BALB/c→BALB/c嵌合体即使在骨髓移植后的前3周内植入第三方皮肤移植物，也会迅速排斥它们。接受第三方皮肤移植物的异基因嵌合体的胸腺细胞和脾细胞能够对第三方抗原产生相对强烈的混合淋巴细胞反应。将来自第三方供体的二次皮肤移植物移植到已经接受此类皮肤移植物的嵌合体上，会导致第三方移植物迅速被排斥，但供体型皮肤移植物不会被排斥，这表明此类嵌合体已经获得了排斥第三方皮肤移植物的免疫能力。因此，有人认为对第三方皮肤移植物的长期耐受性可能与皮肤移植物中骨髓来源细胞的起源有关。
